Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.
Cleland JGF, Kalra PA, Pellicori P, Graham FJ, Foley PWX, Squire IB, Cowburn PJ, Seed A, Clark AL, Szwejkowski B, Banerjee P, Cooke J, Francis M, Clifford P, Wong A, Petrie C, McMurray JJV, Thomson EA, Wetherall K, Robertson M, Ford I, Kalra PR; IRONMAN Study Group. Cleland JGF, et al. Among authors: wetherall k. Eur Heart J. 2024 Apr 21;45(16):1410-1426. doi: 10.1093/eurheartj/ehae086. Eur Heart J. 2024. PMID: 38446126 Free PMC article. Clinical Trial.
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I; IRONMAN Study Group. Kalra PR, et al. Lancet. 2022 Dec 17;400(10369):2199-2209. doi: 10.1016/S0140-6736(22)02083-9. Epub 2022 Nov 5. Lancet. 2022. PMID: 36347265 Free article. Clinical Trial.
The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction.
Ray R, Ford I, Cleland JGF, Graham F, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Critoph C, Kalra PA, Lane RE, Ludman A, Pellicori P, Petrie MC, Robertson M, Seed A, Squire I, Kalra PR; INVESTIGATORS; CLINICAL TRIALS UNIT AND DATA AND STATISTICAL CENTRE; NURSING AND ADMINISTRATIVE SUPPORT; SPONSOR SUPPORT. Ray R, et al. J Card Fail. 2023 Nov 4:S1071-9164(23)00383-4. doi: 10.1016/j.cardfail.2023.10.006. Online ahead of print. J Card Fail. 2023. PMID: 37926238 Free article.
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies.
Osmanska J, Brooksbank K, Docherty KF, Robertson S, Wetherall K, McConnachie A, Hu J, Gardner RS, Clark AL, Squire IB, Kalra PR, Jhund PS, Muntendam P, McMurray JJV, Petrie MC, Campbell RT. Osmanska J, et al. Among authors: wetherall k. Eur Heart J Cardiovasc Pharmacother. 2024 Jan 5;10(1):35-44. doi: 10.1093/ehjcvp/pvad073. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 37804170 Free PMC article.
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N. Lee MMY, et al. Among authors: wetherall k. Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13. Circulation. 2021. PMID: 33186500 Free PMC article. Clinical Trial.
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees. Macdougall IC, et al. N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26. N Engl J Med. 2019. PMID: 30365356 Free article. Clinical Trial.
Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.
Macdougall IC, Bhandari S, White C, Anker SD, Farrington K, Kalra PA, Mark PB, McMurray JJV, Reid C, Robertson M, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees. Macdougall IC, et al. J Am Soc Nephrol. 2020 May;31(5):1118-1127. doi: 10.1681/ASN.2019090972. Epub 2020 Apr 6. J Am Soc Nephrol. 2020. PMID: 32253271 Free PMC article. Clinical Trial.
Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, Hall Barrientos P, Wetherall K, Roditi G, AlHummiany B, Berry C, Campbell RT, Chong V, Coyle L, Docherty KF, Dreisbach JG, Kuehn B, Labinjoh C, Lang NN, Lennie V, Mangion K, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Sharma K, Sourbron S, Speirits IA, Thompson J, Welsh P, Woodward R, Wright A, Radjenovic A, McMurray JJV, Jhund PS, Petrie MC, Sattar N, Mark PB. Lee MMY, et al. Among authors: wetherall k. Circulation. 2022 Jul 26;146(4):364-367. doi: 10.1161/CIRCULATIONAHA.122.059851. Epub 2022 Jul 25. Circulation. 2022. PMID: 35877829 No abstract available.
An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.
Thomson PC, Mark PB, Robertson M, White C, Anker SD, Bhandari S, Farrington K, Jardine AG, Kalra PA, McMurray J, Reddan D, Wheeler DC, Winearls CG, Ford I, Macdougall IC; PIVOTAL Investigators and Committees. Thomson PC, et al. Kidney Int Rep. 2022 May 18;7(8):1793-1801. doi: 10.1016/j.ekir.2022.05.008. eCollection 2022 Aug. Kidney Int Rep. 2022. PMID: 35967105 Free PMC article.
Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
Mackenzie IS, Hawkey CJ, Ford I, Greenlaw N, Pigazzani F, Rogers A, Struthers AD, Begg AG, Wei L, Avery AJ, Taggar JS, Walker A, Duce SL, Barr RJ, Dumbleton JS, Rooke ED, Townend JN, Ritchie LD, MacDonald TM; ALL-HEART Study Group. Mackenzie IS, et al. Lancet. 2022 Oct 8;400(10359):1195-1205. doi: 10.1016/S0140-6736(22)01657-9. Lancet. 2022. PMID: 36216006 Free article. Clinical Trial.
51 results